• Manuela Casula, Alberico Luigi Catapano, Rossana Piccinelli, Enrica Menditto, Lamberto Manzoli, Luisa De Fendi, Valentina Orlando, Maria Elena Flacco, Marco Gambera, Alessandro Filippi, and Elena Tragni.
• Am J Manag Care. 2014 May 1; 20 (5): e138-45.

ObjectivesTo analyze adherence to antiosteoporosis drugs (AODs) and to assess the influence of patient-related and drug-related factors.Study DesignObservational, retrospective study.MethodsData on prescriptions for AODs from 2007 through 2008 were retrieved from administrative databases of 10 Italian local health units. Key measurements included compliance and persistence at 1 year. Multivariate regression analyses were performed to estimate adjusted risk ratios for compliance less than 80% and adjusted hazard ratios for no persistence.ResultsOf 40,004 new patients (89.9% women, mean age 69.8 years), 84.0% were treated with bisphosphonates and 74.6% of administration regimens were weekly. Overall, 75.1% of patients had suboptimal levels of compliance and 84.7% were not persistent; almost one-third had only 1 prescription. In regression analyses, younger age, change of drug, and concomitant corticosteroid therapy were significantly associated to compliance and persistence in both genders. In women, weekly and monthly regimens reduced the risk for poor compliance (sex-adjusted relative risks 0.729 [0.697-0.762], 0.846 [0.817-0.876], respectively) and no persistence (sex-adjusted hazard ratios 0.591 [0.541-0.646], 0.508 [0.461-0.560], respectively) compared with a daily regimen.ConclusionsIn our study, 75% of subjects had discontinuous treatment and inadequate drug supply. Age and frequency of administration were strongly associated with adherence. Improvement is urgently needed, and occasional prescriptions represent the main target.

23 keywords...

hide…